JP2022514759A5 - - Google Patents

Info

Publication number
JP2022514759A5
JP2022514759A5 JP2021535827A JP2021535827A JP2022514759A5 JP 2022514759 A5 JP2022514759 A5 JP 2022514759A5 JP 2021535827 A JP2021535827 A JP 2021535827A JP 2021535827 A JP2021535827 A JP 2021535827A JP 2022514759 A5 JP2022514759 A5 JP 2022514759A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
approximately
vlp
gene group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514759A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067961 external-priority patent/WO2020132510A1/en
Publication of JP2022514759A publication Critical patent/JP2022514759A/ja
Publication of JP2022514759A5 publication Critical patent/JP2022514759A5/ja
Pending legal-status Critical Current

Links

JP2021535827A 2018-12-20 2019-12-20 ノロウイルスワクチン製剤及び方法 Pending JP2022514759A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782733P 2018-12-20 2018-12-20
US62/782,733 2018-12-20
PCT/US2019/067961 WO2020132510A1 (en) 2018-12-20 2019-12-20 Norovirus vaccine formulations and methods

Publications (2)

Publication Number Publication Date
JP2022514759A JP2022514759A (ja) 2022-02-15
JP2022514759A5 true JP2022514759A5 (https=) 2022-12-28

Family

ID=71101884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535827A Pending JP2022514759A (ja) 2018-12-20 2019-12-20 ノロウイルスワクチン製剤及び方法

Country Status (14)

Country Link
US (1) US20220054621A1 (https=)
EP (1) EP3897712A4 (https=)
JP (1) JP2022514759A (https=)
KR (1) KR20210114941A (https=)
CN (1) CN113453711A (https=)
AR (1) AR117462A1 (https=)
AU (1) AU2019404430A1 (https=)
BR (1) BR112021012181A2 (https=)
CA (1) CA3123860A1 (https=)
CO (1) CO2021009379A2 (https=)
IL (1) IL284233A (https=)
MX (1) MX2021007502A (https=)
SG (1) SG11202106628YA (https=)
WO (1) WO2020132510A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
EP4112074A1 (en) 2011-07-11 2023-01-04 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
WO2022143282A1 (zh) * 2020-12-30 2022-07-07 远大赛威信生命科学(南京)有限公司 诺如病毒病毒样颗粒、免疫组合物或试剂盒及其用途
US20240238401A1 (en) 2021-05-21 2024-07-18 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
WO2024202045A1 (ja) * 2023-03-31 2024-10-03 デンカ株式会社 腸管へのウイルス特異的な抗体誘導が可能なノロウイルスワクチン
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2514316T3 (es) * 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
CN104740624B (zh) * 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
NO2324113T3 (https=) * 2008-08-08 2018-07-28
US20110070260A1 (en) * 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
CA2787666A1 (en) * 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
EP4112074A1 (en) * 2011-07-11 2023-01-04 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations

Similar Documents

Publication Publication Date Title
JP2022514759A5 (https=)
Christensen et al. Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8+ T-cell memory
Zhang et al. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity
Mina et al. Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice
Hessel et al. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses
Ye et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms
Marathe et al. Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A (H5N1) virus infection in mice
Maes et al. Recent approaches in hantavirus vaccine development
Osterhaus et al. Towards universal influenza vaccines?
Shinya et al. Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses
JP2009539965A5 (https=)
JP2016538885A5 (https=)
JP2017515508A5 (https=)
JP2014523878A5 (https=)
JP2017526689A5 (https=)
US11123421B2 (en) Cold adapted and virulence factor deleted live attenuated vaccine suitable for mucosal delivery
WO2023024609A1 (zh) 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗
JP2022172244A5 (https=)
CN103221064A (zh) 抗流感病毒的免疫方法及其组合疫苗
JP2019500320A5 (https=)
Huhti et al. Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography
Feitelson et al. Hepatitis B x (HBx) as a component of a functional cure for chronic hepatitis B
CN107208071B (zh) 用于流感病毒的减弱活疫苗
JP2016528176A5 (https=)
Özcengiz et al. Two formulations of coronavirus disease‐19 recombinant subunit vaccine candidate made up of S1 fragment protein P1, S2 fragment protein P2, and nucleocapsid protein elicit strong immunogenicity in mice